GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medesis Pharma SA (XPAR:ALMDP) » Definitions » Debt-to-Revenue

Medesis Pharma (XPAR:ALMDP) Debt-to-Revenue : 17.42 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Medesis Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Medesis Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €1.08 Mil. Medesis Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Medesis Pharma's annualized Revenue for the quarter that ended in Jun. 2024 was €0.06 Mil. Medesis Pharma's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 17.42.


Medesis Pharma Debt-to-Revenue Historical Data

The historical data trend for Medesis Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medesis Pharma Debt-to-Revenue Chart

Medesis Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 7.75 - - - 4.00

Medesis Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - 2.24 18.75 17.42

Competitive Comparison of Medesis Pharma's Debt-to-Revenue

For the Biotechnology subindustry, Medesis Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medesis Pharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medesis Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Medesis Pharma's Debt-to-Revenue falls into.


;
;

Medesis Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Medesis Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Medesis Pharma's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.08 + 0) / 0.062
=17.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Medesis Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medesis Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medesis Pharma Business Description

Traded in Other Exchanges
Address
Loree des Mas, Avenue du golf, Baillargues, Montpellier, FRA, 34670
Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.

Medesis Pharma Headlines

No Headlines